These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29496352)

  • 1. Patient prioritisation in HCC treatment: All (good) things come in threes.
    Wörns MA; Galle PR
    J Hepatol; 2018 Jun; 68(6):1311-1312. PubMed ID: 29496352
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular targets for HCC and future treatments.
    Allaire M; Nault JC
    J Hepatol; 2017 Jan; 66(1):234-235. PubMed ID: 27838136
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical features, etiology, and survival of hepatocellular carcinoma among different countries.
    Omata M; Dan Y; Daniele B; Plentz R; Rudolph KL; Manns M; Piratvisuth T; Chen DS; Tateishi R; Chutaputti A
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S40-9. PubMed ID: 12000592
    [No Abstract]   [Full Text] [Related]  

  • 4. [Multimodal therapy including hepatectomy for multiple hepatocellular carcinomas].
    Yamanaka N; Yasui C; Kitayama Y; Hayashi K; Mitsunobu M; Shiba T; Okabayashi K; Kishi K; Mori T; Suesada Y
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():717-20. PubMed ID: 11762044
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pre and post operative nutritional management for the patients with hepatoma].
    Ohtani Y; Tanaka Y; Makuuchi H
    Nihon Rinsho; 2001 May; 59 Suppl 5():597-600. PubMed ID: 11439606
    [No Abstract]   [Full Text] [Related]  

  • 6. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changed diagnosis and treatment in hepatocellular carcinoma].
    Bender J
    Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1618. PubMed ID: 8815400
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor size remains key for prediction of hepatocellular carcinoma recurrence after liver transplantation.
    Earl TM; Chapman WC
    Ann Surg Oncol; 2011 May; 18(5):1217-8. PubMed ID: 21327456
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan.
    Toyoda H; Kumada T; Tada T; Sone Y; Kaneoka Y; Maeda A
    J Gastroenterol Hepatol; 2011 Dec; 26(12):1765-71. PubMed ID: 21615793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Staging systems for hepatocellular carcinoma: should we all use the BCLC system?
    Marrero JA
    J Hepatol; 2006 Apr; 44(4):630-2. PubMed ID: 16503077
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of treatment response in hepatocellular carcinoma: a review of the literature.
    Maida M; Cabibbo G; Brancatelli G; Genco C; Alessi N; Genova C; Romano P; Raineri M; Giarratano A; Midiri M; Cammà C
    Future Oncol; 2013 Jun; 9(6):845-54. PubMed ID: 23718305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recurrent hepatocellular carcinoma].
    Ishizaki Y; Kawasaki S
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):991-4. PubMed ID: 23986041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of selective internal radiation therapy in challenging cases of liver-predominant unresectable hepatocellular carcinoma.
    Malfertheiner P; Verslype C; Kolligs FT; Schütte K; Vandecaveye V; Paprottka PM; Ricke J
    Future Oncol; 2014 Nov; 10(15 Suppl):17-27. PubMed ID: 25478762
    [No Abstract]   [Full Text] [Related]  

  • 14. [Personalized healthcare in hepatocellular carcinoma. Multi-society Italian position paper.].
    Trevisani F; Garuti F; Neri A
    Recenti Prog Med; 2018 Jan; 109(1):38-45. PubMed ID: 29451521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of hepatocellular carcinoma after liver transplantation: an update.
    Mazzola A; Costantino A; Petta S; Bartolotta TV; Raineri M; Sacco R; Brancatelli G; Cammà C; Cabibbo G
    Future Oncol; 2015; 11(21):2923-36. PubMed ID: 26414336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging and downstaging to transplantation in hepatocellular carcinoma.
    Ettorre GM; Levi Sandri GB; Santoro R; Lepiane P; Colasanti M; Vennarecci G
    Future Oncol; 2014 Nov; 10(15 Suppl):61-3. PubMed ID: 25478770
    [No Abstract]   [Full Text] [Related]  

  • 17. [Complications after TACE in HCC - complications after transarterial chemoembolization (TACE) in hepatocellular carcinoma].
    Schneeweiß S; Horger M; Ketelsen D; Ioanoviciu SD
    Rofo; 2015 Feb; 187(2):79-82. PubMed ID: 25629286
    [No Abstract]   [Full Text] [Related]  

  • 18. The prognostic significance of clinical and pathological features in hepatocellular carcinoma.
    Qin LX; Tang ZY
    World J Gastroenterol; 2002 Apr; 8(2):193-9. PubMed ID: 11925590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma.
    Shao YY; Liu TH; Lee YH; Hsu CH; Cheng AL
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1336-41. PubMed ID: 26860846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization for hepatocellular carcinoma arising in a hepatitis C virus-seropositive renal allograft recipient.
    Läuffer JM; Maurer CA; Marti HP; Borner MM; Schilling MK; Büchler MW
    Transplant Proc; 1999 May; 31(3):1710-2. PubMed ID: 10331046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.